For the quarter ending 2026-03-31, MNPR has $137,983,725 in assets. $2,589,313 in debts. $52,544,263 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 52,544,263 | 127,677,360 | 39,501,936 | |
| Investments | 84,948,677 | 15,998,427 | 13,748,473 | |
| Other current assets | 250,903 | 414,825 | 497,294 | |
| Total current assets | 137,743,843 | 144,090,612 | 53,747,703 | |
| Operating lease right-of-use asset | 239,882 | 106,666 | 118,170 | |
| Total assets | 137,983,725 | 144,197,278 | 53,865,873 | |
| Accounts payable, accrued expenses and other current liabilities | 2,457,748 | 2,568,549 | 1,583,613 | |
| In-process r and d accrued expenses | - | 0 | 0 | |
| Total current liabilities | 2,457,748 | 2,568,549 | 1,583,613 | |
| Operating lease liability - non-current | 131,565 | 70,881 | 80,366 | |
| Total liabilities | 2,589,313 | 2,639,430 | 1,663,979 | |
| Common stock, par value of 0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at march 31, 2026, and december 31, 2025, respectively | 6,699 | 6,663 | 6,127 | |
| Additional paid-in capital | 228,691,772 | 225,848,222 | 132,989,324 | |
| Accumulated other comprehensive income (loss) | 98,521 | 11,698 | 77,577 | |
| Retained earnings (accumulated deficit) | -93,402,580 | -84,308,735 | -80,871,134 | |
| Total stockholders equity | 135,394,412 | 141,557,848 | 52,201,894 | |
| Total liabilities and stockholders equity | 137,983,725 | 144,197,278 | 53,865,873 | |
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)